[Skip to Content]
[Skip to Content Landing]
September 8, 1975

Treatment of Spasticity in Multiple Sclerosis With Dantrolene

Author Affiliations

University of Minnesota Medical School Minneapolis

JAMA. 1975;233(10):1046. doi:10.1001/jama.1975.03260100016002

To the Editor.—  The review article on dantrolene sodium (231:862, 1975) was read with great interest.We have conducted a double-blind, placebo-controlled, trial of this drug in a group of patients with multiple sclerosis, on an outpatient basis. Since the results of our study appeared to be different from those of the article in The Journal, we wish to report them here. Twenty-three patients took part in the study. Spasticity in the lower extremities was prominent in all patients; 11 suffered from severe disability, and were confined to a wheelchair.After an initial base-line evaluation, the patients were randomly allocated to the drug (12 patients) and the placebo (11 patients) groups. Treatment with dantrolene sodium or appropriate placebo was then started at 25 mg four times a day, and increased at weekly increments of 100 mg, if tolerated, up to a maximum daily dose of 800 mg. Evaluations were made again